ABSTRACT

The present invention relates to a pharmaceutical combination. The pharmaceutical combination comprises a glucokinase activator or a pharmaceutically acceptable salt of same, an isotope labeled analogue of same, a crystal form, hydrate, solvate, diastereomer or enantiomer form of same, and a PPAR receptor activator. The present invention further relates to a pharmaceutical composition, a fixed dose combination formulation, and a preparation method for and uses of the pharmaceutical composition and the fixed dose combination formulation.